At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Jun 17, 2026 at 12:36 ET
Spero Therapeutics and GSK announced FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for complicated urinary tract infections (cUTIs) in adults with limited or no alternative oral options. The approval, based on the PIVOT-PO Phase III trial demonstrating non-inferiority to IV imipenem-cilastatin, transforms Spero from a clinical-stage to a commercial-stage biopharma company and unlocks a $6B+ annual US healthcare cost market with GSK as commercialization partner.
- FDA approved Utebzi (tebipenem pivoxil) for cUTIs including pyelonephritis, first and only oral carbapenem antibiotic in the US
- Approval based on PIVOT-PO Phase III trial: 58.5% overall success rate (oral) vs 60.2% (IV imipenem-cilastatin); adjusted treatment difference −1.3% (95% CI −7.5%, 4.8%)
- GSK holds exclusive global license (excluding select Asian territories) and will lead commercialization; Spero sub-licensed back for certain development work
- Product anticipated to be available to US patients by end of 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access